ASA 2026 Fascial Plane Block Mandate: What ASCs Must Do Now

The Problem Nobody in Your ASC Is Talking About Yet

Let me describe a Tuesday morning I lived last year at our Miami surgery center. A plastic surgeon had three back-to-back cases: a bilateral mastectomy with immediate implant reconstruction, an abdominoplasty, and a revision breast augmentation. All cash-pay. All billing between $12,000 and $25,000 per case. All patients expecting to walk out of our ASC that afternoon feeling like they were well cared for.

The CRNA on call that day was excellent — fifteen years of experience, sharp instincts. But we had no formal fascial plane block protocol embedded in our workflow. Pain management was largely reactive: fentanyl intraoperatively, a ketorolac bolus at closure, maybe some bupivacaine field infiltration from the surgeon. Postoperatively, PACU times stretched. One patient needed an unplanned admission because her pain was an eight out of ten two hours post-op. Another got a second dose of IV morphine that pushed her discharge past the window her husband had driven three hours to meet. The surgeon was frustrated. I was frustrated. And one patient wrote a two-star review that mentioned "waking up in agony."

That is a pain management failure — and it is also an operational failure, a revenue risk, and in 2026, increasingly a standard-of-care failure. Because the American Society of Anesthesiologists has now told us, in unambiguous language, what we should have been doing all along.

What the ASA 2026 Guideline Actually Says

In January 2026, Anesthesiology published the 2026 American Society of Anesthesiologists Practice Guideline on Perioperative Pain Management Using Local and Regional Analgesia for Cardiothoracic Surgeries, Mastectomy, and Abdominal Surgeries (Anesthesiology 2026;144:19-43). This is not a consensus statement or a quality improvement bulletin. This is a formal ASA practice guideline — the kind of document that gets cited in malpractice cases and credentialing reviews.

Here is what the Task Force strongly recommends:

• Fascial plane blocks to reduce pain and opioid requirements in the first 24 hours postoperatively for adults undergoing open cardiothoracic, abdominal, retroperitoneal, and pelvic surgeries

• Fascial plane blocks for adults undergoing mastectomy

• Fascial plane blocks for adults undergoing minimally invasive abdominal procedures

• For pediatric patients: strong recommendation for open cardiac or thoracic surgery; conditional recommendation for open hernia repair

Conditional recommendations — meaning evidence supports use but patient-specific factors may guide decision-making — extend to minimally invasive cardiothoracic surgeries and open hernia repair in adults. As a plain-language summary from Guideline Central confirms, this framework covers both adult and pediatric populations and spans a broad procedural spectrum.

Corresponding author Karen B. Domino, MD, MPH, of the University of Washington, put it plainly in Physicians Weekly: "A multimodal analgesic regimen that leverages a combination of nonopioid analgesics with different mechanisms of action is recommended." Fascial plane blocks are not a premium add-on anymore. They are the recommended architecture of the analgesic plan.

Why This Maps Directly to Your Plastic Surgery and ASC Caseload

If you are running a plastic surgery-focused ASC — or if you are a CRNA providing anesthesia for one — read that procedure list again. Mastectomy. Open abdominal surgery. Minimally invasive abdominal procedures. That is your abdominoplasty, your bilateral reduction mammaplasty, your DIEP flap harvest in the outpatient hybrid suite, your laparoscopic port placement. The procedures covered by this guideline are not esoteric cardiac cases happening in academic medical centers. They are on your OR schedule right now.

The scale of this matters too. According to the 2026 Preface to Outpatient Anesthesia in Anesthesiology Clinics, the United States had approximately 6,223 Medicare-certified ASCs performing up to 70 million procedures per year in 2023 — up from roughly 2,700 centers performing 6 million procedures annually in 2000. By 2033, projections point to 109 million procedures per year. We are scaling surgical volume at a rate that makes protocol standardization not a nice-to-have but an operational necessity.

The private-pay math sharpens this further. A bilateral mastectomy with reconstruction at a private plastic surgery ASC can bill $18,000 to $25,000 cash-pay. An abdominoplasty package runs $12,000 to $18,000. An unplanned admission from uncontrolled post-op pain does not just cost you the next case — it can cost you the surgeon relationship, the patient referral pipeline, and your facility's same-day discharge metrics. Pain management is a business continuity issue dressed up in a clinical gown.

Specific Blocks, Specific Cases: A Clinical Framework for Your Team

Let me get concrete, because "fascial plane blocks" is a category, not a prescription. Here is how I think about matching blocks to the plastic surgery ASC caseload in the context of the new guideline:

• Mastectomy / breast reconstruction: The Pectoral Nerve blocks (PECS I and PECS II) and the Serratus Anterior Plane (SAP) block are your workhorses here. I typically run PECS II with 20–30 mL of 0.25% bupivacaine with 1:200,000 epinephrine, confirming spread between the pectoralis minor and serratus anterior under ultrasound. For immediate expander or implant cases, adding a PECS I at the pecto-pectoral fascial plane provides coverage of the medial breast and sternum. These patients wake up asking when surgery is starting. That is the goal.

• Abdominoplasty / open abdominal surgery: The Transversus Abdominis Plane (TAP) block — subcostal, lateral, or posterior approach depending on incision — combined with an Erector Spinae Plane (ESP) block at T9-T10 gives you somatic and dorsal ramus coverage that dramatically reduces intraoperative fentanyl requirements and smooths PACU recovery. I target 20 mL of 0.5% ropivacaine per side for TAP in robust adults, adjusting for weight and renal function.

• Minimally invasive abdominal cases (laparoscopic, endoscopic): The guideline's strong recommendation here is important. Even "small" cases like laparoscopic cholecystectomies or port-site hernia repairs benefit from a bilateral subcostal TAP. The block adds maybe eight minutes to your room time. It removes 40 minutes from PACU. The math is obvious.

The multimodal scaffolding around these blocks matters equally. I structure every truncal case with: acetaminophen 1g IV at induction, ketorolac 15–30 mg IV at incision (adjusted for age, weight, and renal function — creatinine above 1.5 mg/dL is a hard stop for me), and dexamethasone 4–8 mg for PONV prophylaxis and adjunct analgesia. Intraoperative opioid use typically drops to a single 50–100 mcg fentanyl dose or less. That is opioid-sparing anesthesia in practice, not in theory.

As NYSORA's plain-language summary of the 2026 guideline notes, clinicians are encouraged to incorporate these blocks into multimodal analgesia protocols — not treat them as supplemental or optional.

The APSF Counterpoint: Why 'Opioid-Free' Dogma Is Also Dangerous

Now here is where the clinical conversation gets more nuanced — and where I think every CRNA and ASC medical director needs to sit with some intellectual honesty.

In May 2026, the Anesthesia Patient Safety Foundation published a significant counterpoint from researchers at Vanderbilt: "Reconsidering Opioid-Sparing Anesthesia — The Case for Individualized Multimodal Analgesia Care" (Schirle & Burns, APSF 2026). The article warns that rigid, non-individualized opioid-sparing protocols can introduce patient safety risks including inadequate analgesia, timing mismatches, renal complications, bleeding risk from NSAIDs, and postoperative monitoring challenges.

This is not an argument against fascial plane blocks or multimodal analgesia. It is an argument against protocol as ideology. And they are right. I have seen ASC anesthesia teams — often under administrative pressure to hit an "opioid-free'" label — push ketorolac into patients with a creatinine of 1.8 mg/dL, or hold all opioids from a chronic pain patient undergoing a lengthy reconstructive procedure, resulting in breakthrough pain crises that consumed two nurses and a recovery bay for three hours.

The appropriate synthesis of these two 2026 documents — the ASA guideline and the APSF counterpoint — is this: fascial plane blocks should be your default architecture for eligible truncal procedures, but the analgesic plan must remain individualized. That means thorough preoperative assessment of renal function, bleeding risk, chronic opioid tolerance, BMI (which affects block spread and dosing), and patient-reported pain sensitivity. It means protocol plus judgment, not protocol instead of judgment.

The Preoperative Assessment Problem Nobody Wants to Admit

Here is the operational gap that makes all of this harder than it needs to be: most ASCs running high-volume plastic surgery schedules do not have a systematic preoperative screening workflow that feeds the CRNA the right information before they walk into that room.

To execute a safe, individualized fascial plane block protocol, your CRNA needs to know — before the block is drawn up — whether the patient has a creatinine above 1.5 mg/dL (NSAID decision), a platelet count below 100,000 (regional anesthesia risk stratification), documented chronic opioid use (expectation management and dosing adjustment), and any coagulopathy or anticoagulant use that affects needle placement risk. They also need to know about prior surgeries that may have altered fascial anatomy, obesity (BMI above 40 changes depth and volume calculations significantly), and patient-reported anxiety or pain catastrophizing scores that predict poor block satisfaction even when technically perfect blocks are placed.

That data exists — in the patient's history, in their labs, in their medication list. But in most ASC workflows, it arrives as a stack of paper or a fragmented EHR note the morning of surgery. The CRNA is synthesizing it in the holding area while the surgeon is asking about start time.

This is exactly the gap that MyPreOp.ai was built to close. Our platform performs an AI-guided preoperative assessment that screens for the specific comorbidities and lab values relevant to opioid-sparing anesthesia protocols — flagging NSAID contraindications, regional anesthesia risk factors, and chronic pain patterns before the day of surgery, not during it. The platform is designed to meet criteria for Clinical Decision Support under the 21st Century Cures Act, which means it integrates into existing clinical decision workflows without creating a new regulatory burden on your ASC. Our validation study documents the accuracy of these screens against chart-confirmed diagnoses in real ASC populations. The goal is simple: give your CRNA team the individualized patient picture they need to execute the 2026 ASA guideline safely, not just theoretically.

What Your ASC Should Be Doing Before Q4 2026

The ASA is not waiting around. Their official guideline page has announced a new CME course arriving summer 2026 — Guidelines and Advisories: Regional Analgesia for Truncal Surgeries — signaling active implementation push across anesthesia practices nationwide. That CME course is going to reach thousands of CRNAs and anesthesiologists. It is going to change what patients expect. It is going to change what surgeons demand. And it is going to change what plaintiffs' attorneys cite when pain outcomes go sideways.

Here is a practical action checklist for ASC medical directors and CRNA team leads:

1. Audit your current caseload against the ASA 2026 procedure categories. How many of your cases per month fall under "strong recommendation" for fascial plane blocks? That number is your implementation target.

2. Build a procedure-specific block menu — PECS I/II and SAP for breast, TAP and ESP for abdominal — with standardized dosing guidelines, volume calculations by BMI tier, and NSAID/ketorolac eligibility criteria based on creatinine and platelet thresholds.

3. Add block performance time to your OR scheduling model. A well-placed bilateral TAP adds 8–12 minutes. Budget it properly so your surgeons do not perceive blocks as delays.

4. Implement a preoperative screening workflow that delivers CRNA-relevant comorbidity data before the day of surgery. This is where MyPreOp.ai fits — not as a documentation tool, but as a clinical intelligence layer that makes individualized block decisions possible at scale.

5. Train your team on the APSF nuance. The 2026 ASA guideline is the floor. The APSF counterpoint is the ceiling check. Your protocols should reflect both: default to blocks, individualize the rest.

6. Document your block decisions. Whether you perform a block or clinically decide not to, the reasoning should be in the anesthesia record. In 2026, "we don't do blocks here" is not a defensible clinical position for mastectomy or open abdominal cases.

After fifteen years in this field — running anesthesia groups, building ASC protocols, and watching the opioid crisis reshape everything from DEA audits to patient satisfaction scores — I have never seen a guideline shift this operationally significant land this quietly. Most ASC administrators I talk to in Miami and nationally have not fully processed what the January 2026 ASA guideline requires of them. That gap is closing fast.

The question is not whether fascial plane blocks will become your standard of care for opioid-sparing anesthesia in ambulatory surgery. The ASA has answered that. The question is whether your team will be ready to execute that standard safely, consistently, and with the individualized clinical judgment the APSF rightly demands — before the first case where you wish you had been.